Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial

MLA

Trotman, J., et al. Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315702449&authtype=sso&custid=ns315887.

APA

Trotman, J., Buske, C., Tedeschi, A., Matous, J., MacDonald, D., Tam, C., Tournilhac, O., Ma, S., Treon, S., Oriol, A., Ping, J., Briso, E., Arango-Hisijara, I., & Dimopoulos, M. (2021). Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial.

Chicago

Trotman, J, C Buske, A Tedeschi, Jv Matous, D MacDonald, Cs Tam, O Tournilhac, et al. 2021. “Single-Agent Ibrutinib for Rituximab-Refractory Waldenstrom Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate™ Trial.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1315702449&authtype=sso&custid=ns315887.